Abstract
Minimal data exists regarding the use of new-generation new-generation drug-eluting stent (DES) in the treatment of the unprotected left main (ULMCA) coronary artery. Our aim was to assess 2-year clinical outcomes following first-vs. new-generation DES implantation in patients undergoing
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
